A multicentre Italian real-world cohort reported high cumulative disease clearance in patients with moderate-to-severe plaque psoriasis treated with brodalumab over 52 weeks. The study reported a median 97.4% normalized cumulative clinical benefit across the year. Because the study is real-world rather than trial-only, it adds evidence on sustained effectiveness in routine care settings, which can differ from tightly controlled clinical protocols. The cohort design focuses on longitudinal benefit rather than short-term endpoints alone. For dermatology pipeline and payer discussions, durable response signals can influence persistence expectations, sequencing strategies, and real-world value assessments for IL-17 pathway therapies.